[
  {
    "ts": null,
    "headline": "Top 10 High-Yield Dividend Stocks To Consider In May 2025",
    "summary": "May 2025 watchlist: 10 high-yield stocks with a 3.59% average dividend and 14.78% return potential. Read here for an in-depth financial analysis.",
    "url": "https://finnhub.io/api/news?id=754209bf6f7add5ed9057063df56f14ce2e4fbaccbd3ad47db5c2dd742f7b8e5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746138223,
      "headline": "Top 10 High-Yield Dividend Stocks To Consider In May 2025",
      "id": 134178932,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156211986/image_2156211986.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "May 2025 watchlist: 10 high-yield stocks with a 3.59% average dividend and 14.78% return potential. Read here for an in-depth financial analysis.",
      "url": "https://finnhub.io/api/news?id=754209bf6f7add5ed9057063df56f14ce2e4fbaccbd3ad47db5c2dd742f7b8e5"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK): Jim Cramer Agrees – “Merck’s A Good Company”",
    "summary": "We recently published Jim Cramer’s Surprised About US Travel As He Discusses These 18 Stocks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented on the […]",
    "url": "https://finnhub.io/api/news?id=811e0cdf8d6de1fc35e276f3d3c4adb920510eab0e57961e8c74ba2f9a2aeaaf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746134620,
      "headline": "Merck & Co., Inc. (MRK): Jim Cramer Agrees – “Merck’s A Good Company”",
      "id": 134184857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published Jim Cramer’s Surprised About US Travel As He Discusses These 18 Stocks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented on the […]",
      "url": "https://finnhub.io/api/news?id=811e0cdf8d6de1fc35e276f3d3c4adb920510eab0e57961e8c74ba2f9a2aeaaf"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=6cee49d34b6510b5d518f2fc4fbbef2a107c60d2a3732c78fcf19e82ae192b2b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746117120,
      "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "id": 134189514,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=6cee49d34b6510b5d518f2fc4fbbef2a107c60d2a3732c78fcf19e82ae192b2b"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=407d86f86492280dd3b8c3166cf4dcd83c0d84e670270db5063698c9b91f139a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746104415,
      "headline": "Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know",
      "id": 134173574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=407d86f86492280dd3b8c3166cf4dcd83c0d84e670270db5063698c9b91f139a"
    }
  },
  {
    "ts": null,
    "headline": "Top Dividend Stocks To Consider In May 2025",
    "summary": "The United States market has experienced a positive trend, climbing 2.7% in the last week and achieving a 9.6% increase over the past year, with earnings projections indicating an annual growth of 14% in the coming years. In this favorable environment, identifying dividend stocks that offer consistent payouts and potential for capital appreciation can be an effective strategy for investors seeking to balance income generation with growth opportunities.",
    "url": "https://finnhub.io/api/news?id=1adcd9ae054c13e79afa81dca5a0d87627366b692670ca93d6c242fb229e8bd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746099094,
      "headline": "Top Dividend Stocks To Consider In May 2025",
      "id": 134173575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The United States market has experienced a positive trend, climbing 2.7% in the last week and achieving a 9.6% increase over the past year, with earnings projections indicating an annual growth of 14% in the coming years. In this favorable environment, identifying dividend stocks that offer consistent payouts and potential for capital appreciation can be an effective strategy for investors seeking to balance income generation with growth opportunities.",
      "url": "https://finnhub.io/api/news?id=1adcd9ae054c13e79afa81dca5a0d87627366b692670ca93d6c242fb229e8bd2"
    }
  },
  {
    "ts": null,
    "headline": "Halozyme Therapeutics: Still Undervalued Ahead Of Earnings",
    "summary": "Halozymeâs recurring revenue, product strength, and market resilience point to solid upside even with debt and tariff risks. Find out why HALO stock is a buy.",
    "url": "https://finnhub.io/api/news?id=e70bd93195d85172a5774986078460904b07563fe7a30c02135d128a872c4bdc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746090384,
      "headline": "Halozyme Therapeutics: Still Undervalued Ahead Of Earnings",
      "id": 134171840,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2210592791/image_2210592791.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Halozymeâs recurring revenue, product strength, and market resilience point to solid upside even with debt and tariff risks. Find out why HALO stock is a buy.",
      "url": "https://finnhub.io/api/news?id=e70bd93195d85172a5774986078460904b07563fe7a30c02135d128a872c4bdc"
    }
  }
]